BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 16328002)

  • 1. PI3K-Akt signaling is involved in the regulation of p21(WAF/CIP) expression and androgen-independent growth in prostate cancer cells.
    Lu S; Ren C; Liu Y; Epner DE
    Int J Oncol; 2006 Jan; 28(1):245-51. PubMed ID: 16328002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines.
    Paliouras M; Diamandis EP
    Biol Chem; 2008 Jun; 389(6):773-80. PubMed ID: 18627304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
    Yang Q; Titus MA; Fung KM; Lin HK
    J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of prostate cancer cell survival after inhibition of AR expression.
    Cohen MB; Rokhlin OW
    J Cell Biochem; 2009 Feb; 106(3):363-71. PubMed ID: 19115258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
    Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
    Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S; Agoulnik IU; Weigel NL
    Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3 Kinase inhibition on TRAIL-induced apoptosis correlates with androgen-sensitivity and p21 expression in prostate cancer cells.
    Kadowaki Y; Chari NS; Teo AE; Hashi A; Spurgers KB; McDonnell TJ
    Apoptosis; 2011 Jun; 16(6):627-35. PubMed ID: 21437722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line.
    Wang LG; Ossowski L; Ferrari AC
    Cancer Res; 2001 Oct; 61(20):7544-51. PubMed ID: 11606392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells.
    Cao X; Qin J; Xie Y; Khan O; Dowd F; Scofield M; Lin MF; Tu Y
    Oncogene; 2006 Jun; 25(26):3719-34. PubMed ID: 16449965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells.
    Hsieh CL; Cai C; Giwa A; Bivins A; Chen SY; Sabry D; Govardhan K; Shemshedini L
    J Mol Endocrinol; 2008 Jul; 41(1):13-23. PubMed ID: 18469090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of interleukin-6-mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells.
    Xie S; Lin HK; Ni J; Yang L; Wang L; di Sant'Agnese PA; Chang C
    Prostate; 2004 Jun; 60(1):61-7. PubMed ID: 15129430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
    Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
    Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer.
    Yu S; Wang X; Ng CF; Chen S; Chan FL
    Cancer Res; 2007 May; 67(10):4904-14. PubMed ID: 17510420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.
    Xu Y; Chen SY; Ross KN; Balk SP
    Cancer Res; 2006 Aug; 66(15):7783-92. PubMed ID: 16885382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
    Xie Y; Wolff DW; Lin MF; Tu Y
    Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
    Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
    Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor and TGFbeta1/Smad signaling are mutually inhibitory in prostate cancer.
    van der Poel HG
    Eur Urol; 2005 Dec; 48(6):1051-8. PubMed ID: 16257107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zanthoxyli Fructus induces growth arrest and apoptosis of LNCaP human prostate cancer cells in vitro and in vivo in association with blockade of the AKT and AR signal pathways.
    Yang Y; Ikezoe T; Takeuchi T; Adachi Y; Ohtsuki Y; Koeffler HP; Taguchi H
    Oncol Rep; 2006 Jun; 15(6):1581-90. PubMed ID: 16685399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53.
    Nesslinger NJ; Shi XB; deVere White RW
    Cancer Res; 2003 May; 63(9):2228-33. PubMed ID: 12727844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple defects in negative regulation of the PKB/Akt pathway sensitise human cancer cells to the antiproliferative effect of non-steroidal anti-inflammatory drugs.
    Lincová E; Hampl A; Pernicová Z; Starsíchová A; Krcmár P; Machala M; Kozubík A; Soucek K
    Biochem Pharmacol; 2009 Sep; 78(6):561-72. PubMed ID: 19433066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.